Glass House Brands (GLAS) Non Operating Investment Income (2021 - 2022)

Glass House Brands' (GLAS) quarterly Non Operating Investment Income came in at -$3.3 million in Q4 2022, up 53.85% year-on-year from -$2.1 million in Q4 2021, and down 100.0% on a QoQ basis from $871.3 billion in Q3 2022.

Glass House Brands (GLAS) Non Operating Investment Income (2021 - 2022) Analysis & Trends

Glass House Brands (GLAS) has 2 years of Non Operating Investment Income data on file, last reported at -$3.3 million in Q4 2022.

  • On a quarterly basis, Non Operating Investment Income rose 53.85% year-over-year to -$3.3 million in Q4 2022; TTM through Dec 2022 was $1439.8 billion, a 153.27% increase from a year earlier, with the FY2022 full-year figure at -$2.0 million, down 132.95% from the prior year.
  • Non Operating Investment Income for Q4 2022 stood at -$3.3 million, down from $871.3 billion in the prior quarter.
  • Over the last five years, Non Operating Investment Income for GLAS reached as high as $871.3 billion in Q3 2022 and fell as low as -$7.2 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn -
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn -
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn -
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -
10 Glass House Brands 873.84 Mn 845.91 Mn 10.02 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 -3.30 Mn
Dec 31, 2022 -3.30 Mn
Sep 30, 2022 871.33 Bn
Sep 30, 2022 871.33 Bn
Dec 31, 2021 -7.16 Mn
Dec 31, 2021 -7.16 Mn
Sep 30, 2021 568.47 Bn
Sep 30, 2021 568.47 Bn
Jun 30, 2021 -19,437.00
Jun 30, 2021 -19,437.00
Mar 31, 2021 6.09 Mn
Mar 31, 2021 6.09 Mn